RPID (Rapid Micro Biosystems) Short-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rapid Micro Biosystems Short-Term Debt?

Rapid Micro Biosystems's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

Rapid Micro Biosystems Short-Term Debt Historical Data

The historical data trend for Rapid Micro Biosystems's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Micro Biosystems Short-Term Debt Chart

Rapid Micro Biosystems Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Rapid Micro Biosystems Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Rapid Micro Biosystems Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Rapid Micro Biosystems Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Rapid Micro Biosystems's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Micro Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Micro Biosystems Inc (NAS:RPID) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Pawtucket Boulevard West, Suite 280, Lowell, MA, USA, 01854

Website

https://www.rapidmicrobio.com

Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.

Executives

Melinda Litherland Pei	director	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Kirk Malloy	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Sean M Wirtjes	officer: Chief Financial Officer	C/O VARIAN, INC., 3120 HANSEN WAY, M/S D-083, PALO ALTO CA 94304-1030
Spignesi Robert G. Jr.	director, officer: President and CEO	C/O RAPID MICRO BIOSYSTEMS, INC., 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Richard S Kollender	director	C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
Kennedy Lewis Capital Partners Master Fund Ii Lp	10 percent owner	111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Darren Richman	10 percent owner	80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Klm Gp Llc	10 percent owner	80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Investment Management Llc	10 percent owner	80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Management Lp	10 percent owner	225 LIBERTY STREET, SUITE 4210, NEW YORK NY 10281
David Chene	10 percent owner	80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Capital Partners Master Fund Iii Lp	10 percent owner	111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Iii Llc	10 percent owner	111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Holdings Ii Llc	10 percent owner	111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Ii Llc	10 percent owner	111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120